MAINTENANCE OF ENDOMETRIOSIS-ASSOCIATED PAIN REDUCTION AND QUALITY OF LIFE IMPROVEMENT IN PHASE 3 EXTENSION STUDIES WITH ELAGOLIX.

被引：2
|
作者：
Taylor, H. S. [1 ]
Johnson, N. [2 ]
Carr, B. [3 ]
Leyland, N. [4 ]
Rechberger, T. [5 ]
Duan, W. R. [6 ]
Peloso, P. M. [6 ]
Soliman, A. M. [6 ]
Schwefel, B. [6 ]
Chwalisz, K. [6 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia
[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[4] McMaster Univ, Hamilton, ON, Canada
[5] Med Univ Lublin, Lublin, Poland
[6] AbbVie, N Chicago, IL USA
来源：
FERTILITY AND STERILITY | 2017年 / 108卷 / 03期
关键词：
D O I：
10.1016/j.fertnstert.2017.07.294
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
O-234
引用
收藏
页码：E96 / E97
页数：2
相关论文
共 50 条
  • [1] Baseline Burden of Endometriosis-Associated Pain among Women in Two Phase 3 Elagolix Studies
    Leyland, Nicholas
    Surrey, Eric
    Soliman, Ahmed M.
    Eichner, Samantha
    Chen, Kun
    Snabes, Michael
    OBSTETRICS AND GYNECOLOGY, 2018, 131 : 186S - 187S
  • [2] LONG-TERM EFFECT OF ELAGOLIX ON THE ENDOMETRIUM: RESULTS FROM TWO PHASE 3 EXTENSION STUDIES IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN.
    Lessey, B. A.
    Diamond, M. P.
    Agarwal, S.
    Dmowski, P.
    Duan, W. R.
    Thomas, J. W.
    Chwalisz, K.
    FERTILITY AND STERILITY, 2017, 108 (03) : E45 - E45
  • [3] Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
    Leyland, Nicholas
    Taylor, Hugh S.
    Archer, David F.
    Peloso, Paul M.
    Soliman, Ahmed M.
    Palac, Hannah L.
    Martinez, Marisol
    Abrao, Mauricio S.
    JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, 2019, 11 (04) : 171 - 180
  • [4] LONG-TERM EFFECT OF ELAGOLIX ON BONE MINERAL DENSITY: RESULTS FROM TWO PHASE 3 EXTENSION STUDIES IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN.
    Archer, D. F.
    Watts, N.
    Gallagher, C.
    Surrey, E.
    Leyland, N.
    Duan, W. R.
    Schwefel, B.
    Peloso, P. M.
    Chwalisz, K.
    FERTILITY AND STERILITY, 2017, 108 (03) : E95 - E95
  • [5] ELAGOLIX REDUCED DYSPAREUNIA AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PREMENOPAUSAL WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN.
    Leyland, N.
    Taylor, H. S.
    Archer, D. F.
    Peloso, P. M.
    Schwefel, B.
    Soliman, A. M.
    Martinez, M.
    Abrao, M. S.
    FERTILITY AND STERILITY, 2018, 110 (04) : E82 - E83
  • [6] THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE.
    Taylor, H. S.
    Surrey, E.
    Soliman, A. M.
    Castelli-Haley, J.
    Rowan, J. P.
    Chwalisz, K.
    Thomas, J. W.
    Schwefel, B.
    Williams, L. A.
    Jain, R. I.
    FERTILITY AND STERILITY, 2016, 106 (03) : E93 - E93
  • [7] HEALTH-RELATED QUALITY OF LIFE IMPROVEMENT IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN DURING TREATMENT.
    Muneyyirci-Delale, O.
    Charles, C.
    Sinaii, N.
    Dalloul, M.
    Stratton, P.
    FERTILITY AND STERILITY, 2014, 102 (03) : E14 - E14
  • [8] Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study
    Acs, Nandor
    O'Brien, Chris
    Jiang, Ping
    Burke, Joshua
    Jimenez, Roland
    Garner, Elizabeth
    Chwalisz, Kristof
    JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, 2015, 7 (02) : 56 - 62
  • [9] Endometriosis-associated pain: a review of quality of life, sexual health and couple relationship
    Rossi, Valentina
    Tripodi, Francesca
    Simonelli, Chiara
    Galizia, Roberta
    Nimbi, Filippo M.
    MINERVA OBSTETRICS AND GYNECOLOGY, 2021, 73 (05) : 536 - 552
  • [10] Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials
    Pokrzywinski, Robin M.
    Soliman, Ahmed M.
    Chen, Jun
    Snabes, Michael
    Diamond, Michael P.
    Surrey, Eric
    Coyne, Karin S.
    FERTILITY AND STERILITY, 2019, 112 (03) : 545 - 551
12345